Kilitch Drugs FY26 Net Profit Rises to ₹2,950.03 Lakhs

Kilitch Drugs (India) Limited has reported its audited financial results for the quarter and year ended 31st March, 2026. The company's consolidated net profit after tax for FY26 rose to ₹2,950.03 lakhs, compared to ₹2,494.01 lakhs in the previous fiscal year. For the fourth quarter (Q4FY26), the consolidated net profit stood at ₹1,488.28 lakhs, an increase from ₹1,021.86 lakhs in the corresponding quarter of the previous year.

Consolidated Financial Performance

The company's consolidated total income from operations for Q4FY26 surged to ₹8,960.27 lakhs from ₹6,122.58 lakhs year-on-year. For the full year FY26, consolidated total income from operations grew to ₹23,547.49 lakhs from ₹19,831.85 lakhs in FY25. Profit before tax for Q4FY26 was recorded at ₹2,021.05 lakhs, compared to ₹1,384.38 lakhs in Q4FY25. Total comprehensive income for the quarter came in at ₹1,167.11 lakhs against ₹928.46 lakhs in the year-ago period.

Metric: Q4FY26 (Audited) Q4FY25 (Audited) FY26 (Audited) FY25 (Audited) Total Income from Operations: ₹8,960.27 lakhs ₹6,122.58 lakhs ₹23,547.49 lakhs ₹19,831.85 lakhs Profit Before Tax: ₹2,021.05 lakhs ₹1,384.38 lakhs ₹3,865.44 lakhs ₹3,447.42 lakhs Net Profit After Tax: ₹1,488.28 lakhs ₹1,021.86 lakhs ₹2,950.03 lakhs ₹2,494.01 lakhs Total Comprehensive Income: ₹1,167.11 lakhs ₹928.46 lakhs ₹2,843.53 lakhs ₹2,380.33 lakhs Basic & Diluted EPS (₹): ₹4.24 ₹6.47 ₹8.91 ₹16.60

Standalone and Capital Structure Updates

On a standalone basis, income from operations for Q4FY26 was ₹7,196.88 lakhs, up from ₹5,630.41 lakhs in Q4FY25. Standalone profit after tax for the quarter stood at ₹1,399.90 lakhs compared to ₹1,137.41 lakhs year-on-year. For the full year FY26, standalone income from operations rose to ₹18,857.43 lakhs, while standalone profit after tax grew to ₹3,239.96 lakhs.

During the quarter ended 31st March, 2026, the company issued 1,74,80,782 fully paid-up equity shares of face value ₹10 each as bonus shares in the ratio of 1:1. Consequently, the paid-up equity share capital as of 31st March, 2026, increased to ₹3,496.16 lakhs from ₹1,608.23 lakhs in the previous year. Reserves (excluding revaluation reserves) were reported at ₹24,469.17 lakhs on a consolidated basis.

Regulatory Compliance

The audited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 15th May, 2026. The statutory auditors issued an unmodified opinion on the financial statements. The results were filed with stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kilitch Drugs (India) Ltd. has notified the stock exchanges of an upcoming board meeting scheduled for Friday, May 15, 2026. The intimation was issued on May 7, 2026, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Board Meeting Agenda

The meeting of the Board of Directors will be convened to consider and approve the audited financial results of the company for the quarter and year ended March 31, 2026. The results will cover both standalone and consolidated financials, providing a comprehensive view of the company's performance for Q4FY26 and the full fiscal year.

Key details of the scheduled board meeting are outlined below:

Parameter: Details Meeting Date: Friday, May 15, 2026 Purpose: Approval of audited financial results (Standalone & Consolidated) Period Under Review: Quarter and year ended March 31, 2026 Regulatory Reference: Regulation 29, SEBI (LODR) Regulations, 2015

Trading Window Closure

In accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, read with the SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018, and the relevant circulars issued by BSE and NSE dated April 2, 2019, the company has implemented a trading window closure. The trading window has been closed with effect from April 1, 2026, and will reopen 48 hours after the financial results are disclosed to the stock exchanges.

The intimation was signed by Mukund Mehta, Managing Director, on behalf of Kilitch Drugs (India) Limited.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.